An observational study in Prostate Cancer, sponsored by CivaTech Oncology. Completed at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.
Sponsored by CivaTech Oncology · Observational
Ongoing follow up for subjects implanted with the Linear Source String for prostate cancer.
This registry is being conducted to provide long term analysis on the use of the linear Civastring source for prostate cancer. Prospective data collection will record and demonstrate biochemical response rates. Long term side effects and adverse events will be monitored.
6,484 studies on the registry are indexed under Prostatic Neoplasms; 1,415 are open to participants now.
This study's enrollment of 60 is below the median of 200 across 1,200 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →CivaTech Oncology is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients currently indicated for brachytherapy, implanted with the linear LDR source for prostate cancer with a life expectancy greater than 5 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
Biochemical Response Rate (PSA)
Time frame: Up to 5 years
Side Effects (IPSS, IIEF, RFAS score)
Time frame: Up to 5 years
Adverse Events
Time frame: Up to 5 years
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jun 2015, a primary completion of Jun 2023 and a completion of Jun 2023. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CivaTech Oncology